

 Early Warning System

EIB-20210512

DIADEM (EGF VD)



Quick Facts

| | |
|-------------------------|--|
| Countries | Italy |
| Financial Institutions | European Investment Bank (EIB) |
| Status | Approved |
| Bank Risk Rating | U |
| Voting Date | 2022-02-24 |
| Borrower | DIADEM SRL |
| Sectors | Education and Health, Industry and Trade |
| Investment Type(s) | Loan |
| Investment Amount (USD) | \$ 8.59 million |
| Project Cost (USD) | \$ 21.47 million |



Project Description

According to the bank website, the project consists of a quasi-equity financing to Diadem, an Italian biotechnology company developing prognostic testing for early detection of Alzheimer's disease.

The proposed transaction will support research and development (R&D) investments to address a high-unmet medical need in the fields of prediction and diagnosis of Alzheimer's Disease (AD). Diadem's technology is offering the unique possibility to detect AD at an early stage or even predict AD in asymptomatic patients, which may provide the great opportunity to start preventive therapies with disease-modifying treatments (DMTs) and/or non-pharmaceutical interventions that may change the progression of the disease.

The project supports ongoing R&D activities conducted by the Promoter and its network of partners, which encompasses universities, research institutes and other private companies (suppliers, etc.). It represents a rational allocation of resources. Furthermore, this project sustains the Promoter's long-term growth through the development of innovative diagnostic tools.



Investment Description

- European Investment Bank (EIB)



| Private Actor 1 | Private Actor 1 Role | Private Actor 1 Sector | Relation | Private Actor 2 | Private Actor 2 Role | Private Actor 2 Sector |
|-----------------|----------------------|------------------------|----------|-----------------|----------------------|------------------------|
| - | - | - | - | DIADEM SRL | Client | - |



Contact Information

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - DIADEM \(EGF VD\)](#) [Original Source]

Media

- [Italy: EIB provides €7.5 million loan for research and development of Diadem's AlzoSure® Predict blo](#)